Avant Sciences, Inc.

NEW YORK, NY · Founded 2023 · CIK 0002009739 · Biotech · Private

Engineered microorganisms and fermentation-based biomanufacturing platform for producing biologics and specialty chemicals

avant.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$175K
1 Form D · Jul 2024
26 months since last filing
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$175,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2637COSMICA Inc.—$200K
2638Ayala Pharmaceuticals, Inc.—$45M
2639YOUNG THERAPEUTICS, LLC——
2640Avant Sciences, Inc.—$175K
2641Renova Therapeutics, Inc.—$167K
2642BIONANOTECH LLC——
2643GREFFEX, INC.—$155K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Avnish DeobhaktaDirector · Executive Officer
  • Paul LeeDirector · Executive Officer

Patents

USPTO · 0 granted of 3
  • Phase Shifting Intravitreal Tamponadeapplication
  • Phase Shifting Intravitreal Tamponadeapplication
  • Phase Shifting Intravitreal Tamponadeapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.